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Abstract
Background: High-dose methotrexate (HDMTX) is used in the treatment of certain malignancies, including
leptomeningeal metastases, systemic non-Hodgkin lymphoma, acute lymphoblastic leukemia, and osteosarcoma. High
circulating levels of methotrexate can cause severe myelosuppression. The present study aimed to examine the
differences in plasma MTX concentrations measured by two immunoassay systems currently available in the
Japanese market, a TDX/FLX analyzer and a TBA-25FR analyzer.
Methods: A total of 69 plasma samples from 16 patients were assayed by a fluorescence polarization immunoassay
technique using a TDx/FLx analyzer (Abbott Diagnostics, Chicago, Illinois, U.S.A.) and a homogeneous enzyme
immunoassay technique using a TBA-25FR analyzer (Toshiba Medical Systems, Tokyo, Japan).
Results: Assay results were very consistent between the two systems, with good correlation 24 h after the start of
treatment (TBA-25FR = 1.06・TDX/FLX, −1.31, r = 0.99), 48 h after the start of treatment (TBA-25FR = 1.00・TDX/
FLX, +0.027, r > 0.99), and 72 h after the start of treatment (TBA-25FR = 1.09・TDX/FLX, +0.011, r > 0.99).
Conclusions: The calibration curve spanned one order of magnitude with a linear working range from the
lowest to the highest standard. The standard deviations show the excellent reproducibility of repeated
measurements at each standard level for both immunoassay systems. However, when using the TBA-25FR, it is
necessary to perform measurements in the low-concentration range with care.
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Background
Methotrexate (MTX; (2S)-2-[[4-[(2,4-diaminopteridin-
6-yl)methylmethylamino] benzoyl] amino] pentanedioic
acid)) is an antimetabolite drug that acts by inhibiting
dihydrofolate reductase, disrupting purine synthesis,
and preventing cell division. This results in the deple-
tion of intracellular pools of reduced folates required
for DNA synthesis. Rapidly dividing malignant cells that re-
quire greater amounts of reduced folates are preferentially
affected by MTX, resulting in the cessation of DNA synthe-
sis and eventual cell death. High-dose MTX (HDMTX) is
used in the treatment of certain malignancies, including
leptomeningeal metastases, systemic non-Hodgkin lymph-
oma, acute lymphoblastic leukemia, and osteosarcoma [1].
Methotrexate is predominantly eliminated by the kidneys
[2–4]. Indeed, 70–90 % of the administered MTX dose is
excreted unchanged in the urine [3]. Despite the fact that
HDMTX is a very effective treatment, plasma MTX con-
centrations may become excessively high in a small propor-
tion of patients, resulting in toxicity and elimination delay
[5]. High circulating levels of methotrexate can cause
severe myelosuppression. Wide inter-individual variability
has been reported for the pharmacokinetic profiles of MTX
in cases treated with HDMTX therapy [6]. The plasma
concentration of MTX at 24 h can predict efficacy, whereas
the plasma concentrations at 48 and 72 h can reflect the
excretion of MTX. Elimination delay is indicated by MTX
concentrations > 1.0 μmol/L at 48 h and > 0.1 μmol/L at
72 h [7, 8]. Therefore, frequent determination of MTX con-
centrations is needed to safely manage individual patients
receiving HDMTX therapy [9, 10]. This determination is
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usually carried out by automated immunoassay because
urgent analysis may be required. A TDX/FLX analyzer
had been used but we were changed to TBA-25FR
analyzer for discontinued measuring reagent for use in
a TDX/FLX analyzer. There is a possibility that results
of blood concentrations in same sample measured by
the different assay systems may differ by those meas-
urement equipment. However, information about the
correlation of the measured values of MTX between
TDX/FLX analyzer and TBA-25FR analyzer is small.
The present study aimed to examine differences in
plasma MTX concentrations measured by two im-
munoassay systems currently available in the Japanese
market. We compared the plasma MTX concentrations




Medical records were reviewed to identify hospitalized
Japanese patients treated with methotrexate at Oita
University Hospital between May 2013 and December
2013. Patients who received HDMTX therapy for cer-
tain malignancies including leptomeningeal metastases,
systemic non-Hodgkin lymphoma, acute lymphoblastic
leukemia, and osteosarcoma were included. This study
was approved by the Ethics Committee of Oita University.
Since blood samples were collected for therapeutic drug
monitoring and laboratory testing as part of routine pa-
tient care, written informed consent was not necessary.
Automatic immunoassay systems
The plasma MTX concentrations were determined by a
fluorescence polarization immunoassay technique using a
TDX/FLX analyzer (Abbott Diagnostics, Chicago, Illinois,
U.S.A.) and a homogeneous enzyme immunoassay tech-
nique using a TBA-25FR analyzer (Toshiba Medical
Systems, Tokyo, Japan). For the measurement of the a
TDX/FLX analyzer and a TBA-25FR analyzer we were
using the TDx-Methotrexate Dynapac. II (Abbott Diag-
nostics, Chicago, Illinois, U.S.A. Lot No.: 35351 M500)
and Nanopia eTDM Methotrexate (SEKISUI MEDICAL
CO., LTD. Tokyo, Japan. Lot No.: 804REL). Assays were
performed at Oita University Hospital according to
manufacturer instructions.
Measurement of plasma methotrexate concentrations
Plasma MTX concentrations were measured by TDX/FLX
and TBA-25FR at 24, 48, and 72 h after the start of treat-
ment. According to manufacturer’s information for the
TDX/FLX analyzer, the lower limit of quantification of the
assay is 0.02 μmol/L. Blood samples exceeding the upper
limit of the calibration range (0.00–1.00 μmol/L) were di-
luted according to the manufacturer’s protocol. According
to manufacturer’s information for the TDx-Methotrexate
Dynapac. II, the intra- and inter-day accuracy were lower
than 115 % at the 0.07, 0.40, 0.80, 5, 50 and 500 μmol/L
concentration. And coefficient of variation values were
less than 15 %. According to manufacturer’s information
for the TBA-25FR analyzer, the lower limit of quantification
of the assay was 0.04 μmol/L. Blood samples exceeding the
upper limit of the calibration range (0.00–1.20 μmol/L)
were diluted according to the manufacturer’s protocol.
According to manufacturer’s information for the Nanopia
eTDM Methotrexate, the intra- and inter-day accuracy
were lower than 115 % at the 0.00, 0.05, 0.15, 0.25, 0.50 and
1.20 μmol/L concentration. And coefficient of variation
values were less than 15 %.
Comparisons between the same samples
They were evaluated for accuracy intra-day, inter-day
and interobserver using the same sample. We used 0.07
(CONTROL Low), 0.4 (CONTROL Middle) and 0.8
(CONTROL High) μmol/L of The Methotrexate II Con-
trols (Abbott, Lot 37001 M100) as spiked MTX concen-
tration. This study performed according to the FDA or
the PMDA guidance for bioanalytical method validation.
Findings
Results
A total of 16 patients (12 men and 4 women) were in-
cluded in the study. Their median (range) age was 32 (8–
73) years and mean body weight was 50.8 (26.6–75.6) kg
Table 1 Patient characteristics and clinical laboratory data
Age (years) 32 (8–73)
Gender [male/female] 12/4
Height (cm) 165 (124.4–178)





CRP (mg/dL) 0.20 (0.02–1.85)
Alb (g/dL) 3.8 (2.7–4.5)
TP (g/dL) 6.4 (4.7–7.4)
T.Bil (mg/dL) 0.66 (0.19–1.74)
AST (IU/L) 28.2 (14.2–177.7)
ALT (IU/L) 33.8 (12.5–198.4)
ALP 322.0 (189.0–514.0)
γ-GTP 49.4 (11.1–222.8)
BUN (mg/dL) 12.2 (2.9–30.6)
SCr (mg/dL) 0.60 (0.23–2.05)
CCr 99.6 (43.5–219.1)
Data are expressed as median and interquartile range unless otherwise stated
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(Table 1). The number of total samples were 69. The num-
ber of samples that were measured at each time point 24,
48, and 72 h after the start of treatment was 23, 18, 18.
The number of samples measured at other than 24, 48,
and 72 hours after the start of treatment was 10.
Assay results were very consistent between the two im-
munoassay systems, with good correlation total samples
after the start of treatment (TBA-25FR = 1.05*TDX/
FLX, −0.29, r = 0.99; Fig. 1a), 24 h after the start of
treatment (TBA-25FR = 1.06*TDX/FLX, −1.31, r = 0.99;
Fig. 1 Scatter plots with fits correlating methotrexate results (μmol/L) obtained by the reference method TBA-25FR with results obtained by TDX/FLX
immunoassay at total samples (a), 24 h (b), 48 h (c), and 72 h (d) after the start of treatment. Assay results were very consistent between the
two immunoassay systems, with good correlation total samples after the start of treatment (TBA-25FR = 1.05*TDX/FLX, −0.29, r = 0.99; Fig. 1a),
24 h after the start of treatment (TBA-25FR = 1.06*TDX/FLX, −1.31, r = 0.99; Fig. 1b), 48 h after the start of treatment (TBA-25FR = 1.00*TDX/FLX,
+0.027, r > 0.99; Fig. 1c), and 72 h after the start of treatment (TBA-25FR = 1.09*TDX/FLX, +0.011, r > 0.99; Fig. 1d)






(μmol/L) (mean ± S.D.)
Accuracy (%) CV (%) Measured concentration
(μmol/L) (mean ± S.D.)
Accuracy (%) CV (%)
0.07 0.077 ± 0.013 110 16.3 0.096 ± 0.011 137.1 11.2
0.4 0.41 ± 0.025 102.5 6.2 0.41 ± 0.016 102.5 4.0






(μmol/L) (mean ± S.D.)
Accuracy (%) CV (%) Measured concentration
(μmol/L) (mean ± S.D.)
Accuracy (%) CV (%)
0.07 0.073 ± 0.010 104.3 14.5 0.96 ± 0.013 137.1 13.1
0.4 0.41 ± 0.018 102.5 4.3 0.43 ± 0.020 107.5 4.6
0.8 0.83 ± 0.045 103.8 5.4 0.93 ± 0.051 116.3 5.4
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Fig. 1b), 48 h after the start of treatment (TBA-25FR =
1.00*TDX/FLX, +0.027, r > 0.99; Fig. 1c), and 72 h after the
start of treatment (TBA-25FR = 1.09*TDX/FLX, +0.011,
r > 0.99; Fig. 1d). The data for intra- and interday precision
and accuracy are presented in Table 2.
Discussion
The time calibration curve showed excellent linearity,
with correlation coefficients generally ≥ 0.99. The cali-
bration curve spanned one order of magnitude with a
linear working range from the lowest to the highest
standard. The standard deviations show the excellent re-
producibility of repeated measurements at each standard
level. Linear regression of correlation data revealed that
the homogeneous enzyme immunoassay technique using
a TBA-25FR analyzer produced positive bias compared
with the fluorescence polarization immunoassay tech-
nique using a TDX/FLX analyzer.
In the low-concentration and high-concentration re-
gions, the TBA-25FR showed less variation when com-
pared to TDX/FLX, but the positive bias needs to be
taken into consideration.
The coefficient of variation values were less than 15 %
for the TBA-25FR. Results were reproducible, although
intra- and inter day accuracy was higher than 130 % at
the 0.07 μmol/L concentration. This slight change means
that although the variation was low and results were re-
producible, the 130 % accuracy at the 0.07 concentration
is an indication of less accuracy at this concentration (or
a positive bias, as mentioned above) (Table 2). Interob-
server precision and accuracy are result similar to the
intra- and inter day accuracy (Table 3). Cause of the re-
sults it was thought to be due to the use of TDx’s QC
sample. Because I perform the examination of the accur-
acy intra-day, inter-day and interobserver in this study
in TDx-Methotrexate Dynapac. II which is QC for TDx,
it is expected that TDx turned out good in comparison
with TBA. The need that I evaluated using a standard
reagent from this result became clear. TBA-25FR
methotrexate assays have inherent limitations at the
0.07 μmol/L and 0.8 μmol/L spiked MTX concentra-
tions, giving higher measured concentrations compared
to the TDX/FLX. At the 0.07 μmol/L concentration, the
accuracy of TBA-25FR immunoassay was lower than
immunoassay by TDX/FLX. The cause is thought to be
that the TBA-25FR analyzer has a higher lower limit of
quantification concentration than the TDX/FLX. Be-
cause an actual value becomes higher than a theoretical
value in the vicinity of detection limit of 0.04 g/mL in
A, in A, it is thought that it is with a high value than B
in the low-concentrated neighborhood.
Conclusions
The TBA-25FR immunoassay system can play a valuable
diagnostic role in patient care as a valuable adjunct to
therapeutic and clinical treatment. It is able to distin-
guish underdosing from overdosing in HDMTX therapy.
However, when using the TBA-25FR, it is necessary to
perform measurements in the low-concentration range
with care.
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